Pevonedistat Plus Azacitidine for Patients With Higher-Risk MDS, CMML, and AML: Mikkael A. Sekeres, MD

For older patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML) with 20% to 30% marrow blasts, treatment options are limited. In the PANTHER study, the results of which were recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Mikkael A. Sekeres, Professor of Medicine and Chief of the Division of Hematology at the Univer...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.